Why NervGen Pharma Corp.’s (NGEN) Stock Is Down 6.81%
As of Thursday, October 01, NervGen Pharma Corp.’s NGEN share price has dipped by 6.81%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Commentary & Analysis
Why NervGen Pharma Corp.’s (NGEN) Stock Is Down 7.85%
As of Thursday, October 01, NervGen Pharma Corp.’s NGEN share price has dipped by 7.85%, which has investors questioning if this is right time to buy.Jenna Brashear
Why NervGen Pharma Corp.’s (NGEN) Stock Is Down 7.33%
As of Thursday, October 01, NervGen Pharma Corp.’s NGEN share price has dipped by 7.33%, which has investors questioning if this is right time to buy.Jenna Brashear
Why NervGen Pharma Corp.’s (NGEN) Stock Is Down 5.29%
As of Friday, September 18, NervGen Pharma Corp.’s NGEN share price has dipped by 5.29%, which has investors questioning if this is right time to buy.Michael Rose
Why NervGen Pharma Corp.’s (NGEN) Stock Is Down 7.49%
As of Friday, September 18, NervGen Pharma Corp.’s NGEN share price has dipped by 7.49%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | NGEN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $175.3 | $492.0 | 27% |
|
| Shares Out (Mil) | 65.3 | 42.8 | 54% |
|
| Institutional Ownership | 87.1% | 82.8% | 55% |
|
| Float (Mil) | 95.3 | 44.4 | 59% |
|
| Beta | 0.69 | 0.71 | 40% |
|
| Avg Daily Volume (000s) | 427 | 376 | 55% |
|
| Price Change (52-week) |
(51.3%) | 55.3% | 18% |
|
| Growth | NGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (29.6%) | (2.0%) | 14% |
|
| EPS (5yr) | (10.3%) | 15.0% | 21 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 7.0% | (15.1%) | 68% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 3 | |
| Current EPS | ($0.105) | ($0.492) | ($0.339) | |
| Month Ago EPS | ($0.108) | ($0.502) | ($0.341) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.077) | ($0.266) | ($0.316) | |
| Year/Year Chg | (59.6%) | 10.6% | (36.9%) | |
| Financials | NGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($44) | ($11) | 17% |
|
| EPS (TTM) | ($0.546) | ($0.700) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | ($7) | 16% |
|
| Net Cash Flow (TTM) (Mil) | $50 | $5 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $122 | $494 | 22% |
|
| Valuation | NGEN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 14.82 | 2.15 | 94% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NGEN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (114.9%) | (22.2%) | 5% |
|
| ROE | (759.2%) | (21.4%) | 0% |
|
| Liabilities to Assets | 80.8% | 32.8% | 76% |
|
| F-Score | 3 | 3 | 18% |
|
NervGen Pharma Corp. did not pass any screens on 10/13/2026.
